Candriam S.C.A. Puma Biotechnology, Inc. Transaction History

Candriam S.C.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$2.85 - $6.58 $1,425 - $3,290	-500 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$6.63 - $9.39 $3,315 - $4,695	500 New	500 $502,000
Q2 2020 Jul 23, 2020	SELL	$7.01 - $13.24 $576,222 - $1.09 Million	-82,200 Closed	0 $0
Q4 2019 Jan 21, 2020	SELL	$6.5 - $10.73 $916,500 - $1.51 Million	-141,000 Reduced 63.17%	82,200 $1,000
Q2 2019 Aug 01, 2019	BUY	$12.3 - $35.76 $2.57 Million - $7.46 Million	208,586 Added 1427.3%	223,200 $2.82 Million
Q1 2019 May 02, 2019	SELL	$20.77 - $42.37 $6.88 Million - $14 Million	-331,123 Reduced 95.77%	14,614 $567,000
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $592,807 - $1.38 Million	29,537 Added 9.34%	345,737 $7.04 Million
Q3 2018 Nov 07, 2018	BUY	$41.2 - $59.85 $8.7 Million - $12.6 Million	211,200 Added 201.14%	316,200 $14.5 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $1.79 Million - $2.53 Million	37,000 Added 54.41%	105,000 $6.21 Million
Q1 2018 May 09, 2018	BUY	$59.7 - $99.25 $1.61 Million - $2.68 Million	27,000 Added 65.85%	68,000 $4.63 Million
Q4 2017 Feb 07, 2018	SELL	$93.85 - $132.45 $1.55 Million - $2.19 Million	-16,500 Reduced 28.7%	41,000 $4.05 Million
Q3 2017 Nov 03, 2017	BUY	$72.0 - $119.75 $4.14 Million - $6.89 Million	57,500	57,500 $6.89 Million

100

28.9M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $136M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.